Physician profile
William A Stephens
NPI 1659357739
$1,693.63
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $435 · 2023: $447 · 2024: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $467.70 | 2021-2024 | |
| Abbvie INC. | $360.83 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $291.98 | 2022-2024 | Dupixent, Libtayo |
| Leo Pharma INC. | $174.81 | 2021-2024 | Adbry |
| Ucb, INC. | $130.61 | 2021-2024 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $105.55 | 2021-2023 | Ilumya |
| Incyte Corporation | $34.99 | 2022-2024 | Opzelura |
| Lilly USA, LLC | $32.90 | 2021-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $27.67 | 2021 | |
| Organogenesis INC. | $23.32 | 2024 | Puraply Am |
| Pfizer INC. | $14.86 | 2022 | |
| Galderma Laboratories, L.P. | $14.41 | 2024 | |
| Dermavant Sciences, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.